Research Study

Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti CTLA-4 Monoclonal Antibody (Checkmate 168: CHECKpoint Pathway for nivoluMAb Clinical Trial Evaluation 168)
Principal Investigator 
Sasha Smiljanic

Overview

Body Locations and Systems 
Melanoma
Disorders and Conditions 
Melanoma
ClinicalTrials.gov# 
NCT02142218
Status 
Closed to Recruitment
Study Start/End 
Jan 1, 2015 to Sep 2, 2019
Locations 
Lions Gate Hospital
Name/Title 
Vall Sahraei, Clinical Trials Nurse Coordinator
Phone 
604-988-3131 ext. 4934
Purpose of Study 

The primary purpose of this study is to provide treatment with Nivolumab to subjects with histologically confirmed stage III (unresectable) or stage IV advanced melanoma who have progressed on or after prior treatment with an anti-CTLA4-containing therapy and for subjects with known BRAF mutation, also progressed on or after treatment with a BRAF inhibitor.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.